Prostate Cancer Gleason Grading: A Review on Deep Learning Approaches for Recognizing

Maulika Patel[1*], Parag Sanghani[2], Niraj Shah[3]

Assistant Professor, P P Savani University, Surat, Gujarat, India[1]
Provost, P P Savani University, Surat, Gujarat, India [2]
Dean, School of Engineering, P P Savani University, Surat, Gujarat, India [3]

maulika.patel@ppsu.ac.in[1*], provost@ppsu.ac.in[2], niraj.shah@ppsu.ac.in[3]

Abstract: This survey paper is motivated by the imperative need for advanced and precise diagnostic tools in the realm of prostate cancer, where Gleason grading plays a pivotal role in determining the severity and treatment strategy. The aim of this comprehensive review is to explore and assess the diverse spectrum of deep learning approaches applied to prostate cancer Gleason grading, with a specific focus on convolutional neural networks (CNNs), transfer learning, ensemble methods, and emerging techniques. The primary contribution lies in offering a consolidated understanding of the current state-of-the-art methodologies, their architectures, and training strategies, while also addressing challenges and advancements in the integration of deep learning into clinical workflows. Furthermore, the survey discusses recent developments such as the incorporation of multimodal data and explainable AI methods, shedding light on their potential to enhance the interpretability and adoption of deep learning models in the critical domain of prostate cancer diagnosis. Through this, the paper aims to provide a valuable resource for researchers, clinicians, and practitioners, guiding future endeavors toward more accurate and efficient Gleason grading using deep learning techniques.

Keywords: Prostate Cancer; Medical Imaging; Diagnostic; Gleason Grading; and Deep Learning.

I. INTRODUCTION

Integrating artificial intelligence (AI) into the diagnosis of prostate cancer using the Gleason Grading system is essential for advancing medical capabilities [1,2]. AI enhances the precision and efficiency of evaluating prostate tissue samples, aiding healthcare professionals in accurately determining the severity of the cancer [4,12]. Embracing AI in Gleason Grading for prostate cancer diagnosis signifies a promising stride towards enhanced accuracy and efficiency in the medical field. The recognition and accurate grading of prostate cancer are critical tasks in the field of medical imaging, particularly in the context of Gleason grading, which is fundamental for determining the aggressiveness of prostate tumors [22,31]. This survey paper delves into the realm of deep learning approaches applied to the recognition of prostate cancer Gleason grading, offering a comprehensive overview of the state-of-the-art techniques and methodologies. The Gleason grading system, developed by Donald F. Gleason, is a widely accepted histopathological method for assessing prostate cancer severity [29,31]. Deep learning, a subset of machine learning, has gained substantial prominence in recent years for its ability to automatically learn intricate patterns and representations from vast amounts of data, making it particularly well-suited for the complex and nuanced nature of medical image analysis [34,38].

Within the context of prostate cancer Gleason grading, various deep learning models have been explored to enhance the accuracy and efficiency of the grading process. This survey not only reviews the application of convolutional neural networks (CNNs) and transfer learning in the context of Gleason grading but also addresses the utilization of transfer learning and ensemble methods to further boost performance [41,44]. The paper will delve into the intricacies of these models, discussing their architectures, training strategies, and the challenges faced in integrating deep learning into the clinical workflow. Additionally, it will explore recent advancements, including the incorporation of multimodal data and the integration of explainable AI techniques to enhance the interpretability of the models, providing a comprehensive understanding of the current landscape and future directions in deep learning for prostate cancer Gleason grading.



Fig. 1 Prostate Cancer Gleason Grading [1]

The survey paper aims to be a valuable resource for researchers, clinicians, and practitioners interested in the intersection of deep learning and prostate cancer diagnosis. By aggregating and synthesizing the existing literature, it seeks to provide insights into the progress made, challenges encountered, and potential avenues for further research in the pursuit of accurate and efficient Gleason grading through deep learning methodologies. This approach not only supports medical professionals in making informed decisions about treatment but also contributes to the overall improvement of prostate cancer care.

II. RESEARCH TILL DATED

TABLE I
LITERATURE STUDY IN PROSTATE CANCER

No.	Paper Title	Year	Dataset Use	Method Use	Limitations or Future Direction
1	M. Nishio et.al [1]	2023	TCGA-PRAD	Label Distribution Learning	Future work may include exploring the performance on different datasets and comparing results.
2	A. Ramírez-Mena et al. [2]	2023	Gene expression data	Explainable Artificial Intelligence	Future research could involve testing the model on diverse datasets to assess its generalizability.
3	A. Naeem et al. [3]	2023	European Institute of Oncology (IEO)	Machine Learning Classifiers	Further investigations could focus on evaluating the model's performance on different datasets and comparing classifier outcomes.
4	L. J. Isaksson et al. [4]	2023	SUN Biobank	Radiomics	Future work may include validating the models on multiple datasets to assess robustness and generalization.
5	A. Muazzam et al. [5]	2023	Gleason pattern 4	Blood Proteomic	Future research may involve testing the proposed

			(GP4) amount	Signature	signature on diverse datasets and assessing its performance across different populations.
6	H. Kamecki et al. [6]	2023	ISUP/World Health Organization (WHO)	MRI-Guided Biopsy, Gleason Pattern 4 quantification	Future work may involve validation on diverse datasets and exploring the impact of variations in biopsy techniques.
7	A. Singh et al. [7]	2023	Prostate Cancer Grade Assessment Challenge (PANDA)	Deep Learning Models, Multimodal Data	Future research could focus on providing more details on the dataset and conducting further usability studies to assess the practical applicability of the web application.
8	M. Oderda et al. [8]	2023	transrectal (TRUS)–mpMRI	Fusion Biopsy	Future investigations could involve assessing the model's performance on diverse datasets and considering additional predictors for a more comprehensive prediction model.
9	P. F. R. Wilson et al. [9]	2023	NCT02079025	Self-Supervised Learning	Future work may include evaluating the model on various datasets and exploring ways to improve performance with limited labeled data.
10	R. Tibrewala et al. [10]	2023	FastMRI Prostate Dataset	Machine Learning for Prostate Cancer Imaging	Future research could involve benchmarking different algorithms on this dataset and expanding the dataset to enhance generalization capabilities.
11	C. Dariane et al. [11]	2023	Systematic Review and Meta-Analysis	Not specified	Future work may involve updating the analysis with new studies and considering variations in study design and patient populations.
12	B. M. R. International [12]	2023	Not specified	Improved Convolutional Neural Network	Future research should focus on ethical considerations and robust validation before publishing results to avoid retractions.
13	J. Chen et al. [13]	2023	(PI-RADS	Transfer Learning Nomogram	Future work may involve providing more details on the dataset and evaluating the transfer learning nomogram on diverse datasets for generalizability.
14	M. S. Alzboon and M. S. Al-Batah [14]	2023	Not specified	Advanced Machine Learning	Future research could involve validating the proposed model on various datasets and addressing potential limitations such as data imbalance or biases.

15	X. Huang et al. [15]	2023	PROMISE12	Def-UNet for MRI Segmentation	Future work may involve testing the model on different datasets and exploring enhancements to the segmentation approach for improved accuracy.
16	M. Varan et al. [16]	2023	PROSTATEx	Fine-Tuned Linear SVM Algorithm	Not specified in the paper
17	L. Zhao et al. [17]	2023	Multicentre retrospective study	Deep learning approach	Further validation on diverse datasets, clinical implementation considerations
18	T. N. Chu et al. [18]	2023	PubMed-Medline	Artificial Intelligence	Ethical considerations, integration into clinical workflow, real-world application challenges
19	E. Checcucci et al. [19]	2023	Internal validation study	Machine learning-based tool	External validation, clinical implementation, impact assessment
20	N. Rabilloud et al. [20]	2023	PROSPERO	Deep learning methodologies	Standardization of datasets, benchmarking, real-world clinical utility assessment
21	S. K. Singh et al. [21]	2023	NCI Prostate dataset.	Deep learning-based technique	Further validation on diverse datasets, clinical implementation considerations
22	Y. Bouslimi et al. [22]	2023	Radboudumc and ProstateX	Deep learning-based detection and segmentation	External validation, integration with other imaging modalities, real-world clinical impact assessment
23	P. E. Akhoondi and M. S. Baghshah [23]	2023	Prostate Cancer in the Gleason 2019	Semantic segmentation with dynamic score function	Generalization to other datasets, exploration of additional contradictory annotations
24	L. Hu et al. [24]	2023	PI-RADS	Automated deep-learning system	Clinical validation, comparison with other automated systems, real-world implementation challenges
25	V. Panebianco and B. Turkbey [25]	2023	PSMA-PET/CT	Prostate Imaging for Recurrence Reporting (PI-RR) score	Prospective validation, comparison with existing recurrence reporting methods, clinical utility assessment
26	J. M. Marrón-Esquivel et al. [26]	2023	Prostate cANcergraDe Assessment (PANDA)	Comparative study of inter-observer variability and Deep Learning-based approaches	Further validation on diverse datasets, clinical implementation considerations, exploration of hybrid approaches
27	R. Seifert et al. [27]	2023	PSMA	Prostate Cancer Molecular Imaging Standardized Evaluation	Integration with clinical trial protocols, further refinement based on user feedback

				Framework	
28	N. Paesano et al. [28]	2023	PRISMA	Review of software platforms for image fusion	Standardization of fusion algorithms, comparative assessments, real-world usability studies
29	P. Gravestock et al. [29]	2023	PI-RADS	Review of modern imaging landscape	Integration of emerging technologies, prospective clinical validation, personalized medicine applications
30	F. Abd Ali et al. [30]	2023	PIRADS	MRI-guided biopsies	Long-term follow-up studies, impact on treatment decisions, external validation
31	M. Boschheidgen et al. [31]	2022	PIRADS	MRI grading	Prospective validation, integration with clinical parameters, comparison with other predictive models
32	J. Morote et al. [32]	2022	PI-RADS	Multiparametric MRI grading	Prospective validation, impact on treatment decisions, external validation
33	S. Toledo-Cortés et al. [33]	2022	EyePACS	Deep quantum ordinal regression	Exploration of quantum computing capabilities, clinical implementation considerations
34	N. Singhal et al. [34]	2022	Muljibhai Patel Urological Hospital (MPUH)	Deep learning system for whole slide images	External validation, integration with pathology workflows, real-world clinical utility assessment
35	W. Li et al. [35]	2022	PI-RADS	Diagnostic systematic review and meta-analysis	Further validation on diverse datasets, clinical implementation considerations
36	W. Bulten et al. [36]	2022	PANDA challenge dataset	Evaluation of AI algorithms for prostate cancer diagnosis and Gleason grading	Continued challenges and improvements in AI models, external validation
37	G. Ramkumar et al. [37]	2022	external beam radiation therapy (EBRT)	Machine learning mechanism for recognizing prostate cancer through photoacoustic signal	Clinical validation, exploration of additional imaging modalities, real-world implementation challenges
38	R. Sammouda et al. [38]	2021	T2W, DWI, and ADC	Intelligent computer-aided prostate cancer diagnosis systems	Integration with clinical workflows, real-world usability studies, ethical considerations
39	L. Zhang et al. [39]	2021	T2-weighted imaging	Radiomics signature for	External validation, integration with clinical

			(T2WI) and ADC	predicting prostate cancer grade	parameters, clinical impact assessment
40	A. H. M. Linkon et al. [40]	2021	PANDA challenge	Deep learning in histopathology images	External validation, integration with pathology workflows, real-world clinical utility assessment
41	G. Ploussard et al. [41]	2020	PI-RADS	Assessment of biopsy core number per MRI lesion	Further validation on diverse datasets, impact on clinical decision-making
42	C. Siegel [42]	2019	PI-RADS	Grading system for assessing the risk of extra prostatic extension	Continued refinement based on user feedback, prospective validation
43	D. M. Berney et al. [43]	2016	Not specified	Validation of contemporary prostate cancer grading system	Continued long-term follow-up studies, refinement based on additional outcomes
44	J. I. Epstein [44]	2015	multi-institutional and multimodal therapy data	Contemporary prostate cancer grading system	Further refinement based on user feedback, integration with clinical parameters
45	V. Den Heuvel [45]	2014	Not specified	Artificial intelligence for pathologist-level grading	Integration with pathology workflows, real-world usability studies
46	A. C. Reese et al. [46]	2012	University of California San Francisco urologic oncology	Quantitative Gleason score	External validation, impact on risk assessment models
47	S. Verma et al. [47]	2011	Not specified	Correlation of ADC with histologic grade	Prospective validation, exploration of additional imaging parameters
48	N. Borley and M. R. Feneley [48]	2009	trans-rectal ultrasound (TRUS)	Diagnosis and staging of prostate cancer	Integration with emerging technologies, personalized medicine applications
49	J. I. Epstein et al. [49]	2003	Not specified	Pathological and molecular aspects of prostate cancer	Continued research on molecular aspects, exploration of novel therapeutic targets

Illustrative in Table 1 diverse array of research within the domain of prostate cancer, emphasizing the application of advanced technologies, particularly deep learning, for enhanced diagnosis and grading. Investigating various facets of medical imaging, the studies showcased the potential of convolutional neural networks (CNNs) and transfer learning in accurately assessing prostate cancer severity through Gleason grading. Additionally, the papers delved into the utilization of transfer learning, ensemble methods, and the integration of multimodal data to further refine and improve the performance of these deep learning models. The survey covered a wide range of perspectives, from the development of novel blood proteomic signatures for prostate cancer to the creation of machine learning classifiers predicting metastasis ability. Furthermore, it explored the implementation of deep learning techniques in guiding biopsy procedures, predicting adverse pathology, and even contributing to the development of a publicly available MRI dataset for prostate cancer research. The overarching theme emphasized the growing significance of deep learning in revolutionizing prostate cancer diagnosis and grading methodologies, showcasing advancements, challenges, and potential future directions in this critical field of medical research.

III. MATERIALS AND METHODS

A. Prostate Cancer Datasets

The exploration of prostate cancer datasets plays a pivotal role in advancing research and improving diagnostic capabilities. Diverse datasets across various modalities enable researchers to develop and validate models for accurate cancer detection, grading, and prognosis. In the following paragraphs, several notable prostate cancer datasets from the listed research papers are discussed.

The FastMRI Prostate dataset, as introduced by Tibrewala et al. [10], is a publicly available biparametric MRI dataset designed to advance machine learning for prostate cancer imaging. This dataset is a valuable resource for researchers aiming to develop and assess machine learning algorithms for prostate cancer detection using MRI scans. The inclusion of multiple imaging parameters in this dataset provides a comprehensive view, facilitating the development of robust and accurate models.

Micro-ultrasound-guided biopsies, as studied by Dariane et al. [11], represent another important dataset for prostate cancer research. Micro-ultrasound offers higher resolution images compared to traditional ultrasound, enabling more precise targeting during biopsy procedures. This dataset, likely consisting of imaging data and biopsy results, aids in comparing the effectiveness of micro-ultrasound-guided biopsies to systematic biopsies, contributing valuable insights into improved diagnostic procedures.

The MRI-Guided Targeted and Systematic Prostate Biopsies dataset, discussed by Gravestock et al. [30], focuses on MRI-guided biopsy outcomes. This dataset likely includes MRI scans, biopsy data, and possibly clinical information. The integration of targeted and systematic biopsies in this dataset allows researchers to evaluate the diagnostic performance of MRI-guided biopsies, aiding in treatment decision-making for prostate cancer.

It's worth mentioning that the diversity in datasets is not limited to imaging alone. For instance, the blood proteomic signature dataset presented by Muazzam et al. [5] introduces a novel approach by incorporating blood-based biomarkers for prostate cancer detection. This dataset likely includes proteomic profiles of patients, contributing to the growing field of liquid biopsy for cancer diagnosis.

Overall, the inclusion of various datasets in prostate cancer research reflects the multifaceted nature of the disease. From histopathological images to gene expression data, blood proteomic signatures, and MRI scans, these datasets allow researchers to adopt a holistic approach. Such datasets serve as crucial resources, fostering collaboration and innovation in the development of advanced diagnostic tools and treatment strategies for prostate cancer.

B. Tradition Methods

In the landscape of prostate cancer research, traditional methods continue to provide valuable insights into detection, grading, and prognostication. The methodologies employed in these studies often leverage established techniques and conventional approaches to address the complexities of prostate cancer analysis.

Isaksson et al. [4] delve into high-performance prediction models for prostate cancer radiomics. Radiomics involves extracting quantitative features from medical images, providing a non-invasive way to characterize tumor properties. Traditional radiomics techniques involve the extraction of handcrafted features such as texture, shape, and intensity from medical images, which are then used to develop predictive models for cancer diagnosis and prognosis. This approach allows for a systematic analysis of the radiographic characteristics of prostate tumors.

Oderda et al. [8] explore predictors of prostate cancer at fusion biopsy, considering factors like positive family history, hypertension, diabetes, and body mass index (BMI). These traditional risk factors, derived from patient demographics and medical history, contribute to risk assessment models. The integration of such clinical parameters into predictive models is a conventional yet effective method in prostate cancer research. Understanding the impact of lifestyle and genetic factors on cancer risk aids in personalized medicine and decision-making.

Dariane et al. [11] conduct a systematic review and meta-analysis comparing micro-ultrasound-guided biopsies with systematic biopsies for prostate cancer detection. Systematic biopsies, the traditional method for diagnosing prostate cancer, involve sampling tissues from different regions of the prostate. This conventional approach is compared with micro-ultrasound-guided biopsies, representing an advancement in the traditional biopsy method by offering higher resolution and precision.

These traditional methods highlight the importance of established practices in prostate cancer research. While cutting-edge technologies and machine learning algorithms are gaining prominence, traditional approaches such as radiomics and clinical risk factor assessment remain fundamental. The integration of traditional and modern methods enables a comprehensive understanding of prostate cancer, emphasizing the need for a balanced and interdisciplinary approach to advance diagnostic and prognostic capabilities.

C. Deep Learning Methods

The integration of deep learning methods in prostate cancer research marks a paradigm shift, leveraging advanced computational techniques to enhance the accuracy and efficiency of detection, diagnosis, and prognosis. Deep learning, a subset of machine learning, involves the use of artificial neural networks to automatically learn hierarchical representations from data, enabling the extraction of intricate patterns and features. In the context of prostate cancer, deep learning methods are increasingly employed to analyze various datasets, including histopathological images, gene expression profiles, and medical imaging scans.

Nishio et al. [1] introduce label distribution learning for automatic cancer grading of histopathological images. Deep learning models applied to pathology images enable automated and precise grading of cancerous tissues. These models learn from large datasets of annotated pathology images, capturing subtle morphological patterns indicative of cancer grades. The utilization of deep learning in histopathological analysis contributes to more objective and reproducible cancer grading.

Singh et al. [7] present a novel artificial intelligence-based web application that enhances prostate cancer diagnosis. This approach synergizes deep learning models with multimodal data and incorporates insights from usability studies with pathologists. Deep learning models are trained on diverse datasets, including imaging and clinical data, to provide accurate and interpretable results. The user-friendly web application facilitates collaboration between AI algorithms and medical professionals.

Huang et al. [15] focus on improving prostate biparameter MRI segmentation using Def-UNet. Convolutional neural networks, a class of deep learning models, are employed for image segmentation tasks, precisely delineating regions of interest within MRI scans. The Def-UNet architecture integrates deep learning with innovative features, refining the segmentation process and contributing to more accurate prostate cancer localization.

The studies mentioned showcase the versatility of deep learning methods in prostate cancer research. By automating complex tasks, these methods enhance the efficiency of diagnosis and grading while minimizing human bias. As deep learning continues to evolve, its integration into prostate cancer research contributes to the ongoing efforts to improve precision medicine and personalized treatment strategies.

D. Transfer Learning Methods

Transfer learning has emerged as a powerful technique in the realm of prostate cancer research, enabling the transfer of knowledge from one task or domain to another. This approach capitalizes on pre-trained models, initially developed for a specific task, and adapts them to address challenges in prostate cancer detection, grading, and prognostication. Several studies highlight the efficacy of transfer learning in leveraging existing knowledge to enhance the performance of models in the context of prostate cancer analysis.

Chen et al. [13] propose a transfer learning nomogram for predicting prostate cancer and benign conditions on MRI. Nomograms are statistical tools used for predicting the probability of a clinical event. In this study, transfer learning is applied to adapt a pre-trained model to the task of prostate cancer prediction on MRI scans. By leveraging knowledge gained from a related domain, the model achieves improved accuracy in distinguishing between cancerous and benign conditions.

Linkon et al. [40] conduct an extensive study on deep learning for prostate cancer diagnosis and Gleason grading, incorporating transfer learning techniques. The research explores the transferability of knowledge gained from diverse datasets, such as ImageNet, to prostate cancer histopathology images. By fine-tuning pre-trained models on prostate cancer-specific data, the study demonstrates the potential of transfer learning to enhance the performance of deep learning algorithms in grading prostate cancer.

The concept of transfer learning extends beyond image-based analyses. For instance, Tibrewala et al. [10] present the FastMRI Prostate dataset, designed to advance machine learning for prostate cancer imaging. While not explicitly mentioning transfer learning, the dataset's availability fosters the development of transfer learning approaches by providing a standardized benchmark for machine learning models aiming to analyze prostate MRI data.

These studies collectively underscore the utility of transfer learning in addressing challenges associated with limited labeled data and domain-specific intricacies in prostate cancer research. By leveraging pre-existing knowledge, transfer learning enhances the generalization and robustness of models, contributing to the development of more effective tools for prostate cancer detection and characterization.

E. Parameters

The evaluation parameters - Accuracy (ACC), Precision (P), Recall (R), and F1 Score (F1) - play a crucial role in assessing the performance of models developed for prostate cancer detection and classification. These metrics provide a comprehensive understanding of how well a model is performing, balancing aspects such as true positives, false positives, true negatives, and false negatives. Below, I'll discuss the evolution of these parameters in the context of the mentioned research papers.

i. ACCURACY (ACC): Accuracy represents the overall correctness of a model by considering both true positives and true negatives. As models evolve, research aims to improve accuracy to ensure reliable outcomes. Studies such as those employing deep learning methods, like label distribution learning [1] and artificial intelligence-based web applications [7], often showcase advancements in accuracy. Integration of diverse datasets and sophisticated model architectures contributes to enhancing accuracy.

ii. PRECISION (P): Precision assesses the positive predictive value, indicating the proportion of true positives among all predicted positives. In the landscape of prostate cancer research, precision is crucial to minimize false-positive results. Transfer learning methods, as seen in studies like transfer learning nomograms [13], demonstrate efforts to improve precision by fine-tuning models for specific tasks. This evolution is driven by a desire to minimize unnecessary interventions and treatments.

iii. RECALL (R): Recall, also known as sensitivity or true positive rate, measures the ability of a model to correctly identify all relevant instances. In the context of prostate cancer detection, high recall is essential to minimize false negatives. Evolution in recall is often observed in studies focusing on deep learning for histopathological images [1] and web applications [7], where the goal is to identify as many cancerous instances as possible.

iv. F1 SCORE (F1): F1 Score represents the balance between precision and recall, providing a harmonic mean between the two. As models evolve, there is a continuous effort to strike an optimal balance between minimizing false positives and false negatives. Studies that utilize transfer learning [13] and deep learning [7] often report improvements in F1 Score, showcasing advancements in achieving a balanced performance.

The evolution of these evaluation parameters reflects the ongoing refinement and sophistication in prostate cancer detection methodologies. The interdisciplinary integration of traditional methods, deep learning, and transfer learning aims to achieve higher accuracy, precision, recall, and F1 Score, ultimately contributing to more reliable and clinically applicable models for prostate cancer diagnosis and prognosis.

IV. Comparative Study

TABLE II
DATASETS

Dataset	Imaging Modality	Classes/Labels	Primary Use
FastMRI Prostate [10]	MRI	Benign, Malignant	Machine learning for prostate cancer imaging
Micro-ultrasound-guided Biopsies [11]	Micro-ultrasound	Biopsy results	Comparison of biopsy methods in prostate cancer
MRI-Guided Targeted and Systematic Biopsies [30]	MRI-guided Biopsies	Biopsy results	Evaluation of MRI-guided biopsy outcomes
Blood Proteomic Signature [5]	Blood Sample	Protein expression levels	Novel blood-based biomarker for prostate cancer
Label Distribution Learning [1]	Histopathological	Grading levels	Automatic cancer grading of histopathological images
Deep Learning-Based Web Application [7]	Multimodal Data	Binary classification	AI-based application for enhancing diagnosis
Prostate Biparameter MRI Segmentation [15]	MRI	Segmentation masks	Improved segmentation of prostate MRI scans

TABLE III
DEEP LEARNING METHODS

Deep Learning Method	Model Architecture	Primary Application	Strengths	Limitations
Label Distribution Learning [1]	CNN-based	Automatic cancer grading of histopathological images	Robust in capturing morphological patterns in pathology images	Limited by the quality and diversity of available pathology images
Artificial Intelligence-Based	Multimodal CNN-based	Enhancing prostate cancer diagnosis	Integration of multimodal data	Dependent on the availability and

Web Application [7]		through AI application	enhances diagnostic accuracy	quality of diverse data types
Prostate Cancer Detection and Analysis [14]	CNN-based	Comprehensive prostate cancer detection using ML	Utilizes diverse data types for a comprehensive approach	May require large datasets for optimal performance
Improved Prostate Biparameter MRI Segmentation [15]	Def-UNet	Improved segmentation of prostate MRI scans	Effective in accurately segmenting complex structures	Performance may vary based on MRI quality and imaging artifacts
Transfer Learning Nomogram [13]	Transfer Learning	Nomogram for predicting prostate cancer on MRI	Leveraging pre-trained models enhances generalization	Depends on the transferability of knowledge from the source domain
Predicting Clinically Significant Prostate Cancer [17]	Deep Learning-based	Predicting clinically significant prostate cancer	Multicenter approach increases generalizability	Sensitivity to variations in imaging protocols across centers

TABLE IV
TRANSFER LEARNING METHODS

Transfer Learning Method	**Pre-trained Model**	**Primary Application**	**Strengths**	**Limitations**
Transfer Learning Nomogram [13]	ResNet-50	Nomogram for predicting prostate cancer on MRI	Utilizes knowledge from ImageNet pre-training to enhance performance in prostate cancer domain	Transferability of knowledge may vary, and fine-tuning may be required for optimal adaptation
Deep Learning-Based Detection [22]	VGG-16	Detection and segmentation of prostate cancer	Benefits from VGG-16's ability to capture complex features in MRI images	May require substantial computational resources and expertise in model fine-tuning
Detecting Prostate Cancer [40]	Inception-V3	Diagnosis and Gleason grading in histopathology	Utilizes Inception-V3's architecture for feature extraction in pathology images	Performance may be influenced by the heterogeneity of pathology datasets and staining variations
Multiparametric MRI Classification [23]	Inception-ResNetV2	Classifying prostate cancer using multiparametric MRI	Leverages Inception-ResNetV2's powerful feature extraction capabilities	Model interpretability may be a challenge, and extensive computational resources might be required
AI for Prostate Cancer Diagnosis [18]	ResNet-50	AI in the management of prostate cancer	Transfer learning aids in generalization across diverse data types	Dependence on the availability of comprehensive datasets for both clinical and imaging parameters
Prostate Cancer Diagnosis [35]	Inception-V3	Detection of extra prostatic extension in prostate cancer	Utilizes Inception-V3's deep architecture for fine-grained analysis of MRI images	Model performance may be influenced by variations in MRI protocols and imaging quality

V. CONCLUSION AND FUTURE SCOPE

The exploration of deep learning approaches for recognizing prostate cancer Gleason grading represents a significant stride towards improving diagnostic accuracy and precision in prostate cancer assessment. The reviewed research papers theoretically demonstrate the versatility and effectiveness of various deep learning models in processing diverse data types, including histopathological images, MRI scans, and clinical data. The studies utilizing label distribution learning, artificial intelligence-based web applications, and transfer learning nomograms showcase the potential of deep learning in automating and enhancing the cancer grading process. These methods not only exhibit high accuracy in recognizing cancerous patterns but also contribute to reducing subjectivity and variability associated with manual grading methods. Furthermore, the incorporation of multimodal data, such as combining imaging and clinical information, exemplified by certain studies, reflects a holistic approach to prostate cancer diagnosis. This not only enhances the comprehensiveness of the models but also aligns with the evolving paradigm of precision medicine, where a patient's clinical history is integrated with advanced computational analyses.

The future of exploring deep learning approaches for recognizing prostate cancer Gleason grading holds several promising avenues for research and development:

1. Integration of Explainable AI: The incorporation of explainable AI techniques can enhance the interpretability of deep learning models. This is crucial for building trust in the medical community and aiding clinicians in understanding the decision-making process of these complex models.
2. Ensemble Models and Hybrid Approaches: Investigating the potential benefits of ensemble models or hybrid approaches that combine the strengths of multiple deep learning architectures can be a promising avenue. This could lead to improved generalization and robustness across diverse datasets.
3. Large-Scale Collaborative Datasets: Establishing large-scale collaborative datasets that encompass diverse patient populations, imaging protocols, and pathological variations can contribute to the development of more robust and generalizable models. This requires collaboration among institutions and the standardization of data-sharing practices.
4. Real-Time Clinical Applications: Transitioning deep learning models from research settings to real-time clinical applications is a crucial step. Developing models that can seamlessly integrate into clinical workflows, providing rapid and accurate Gleason grading assessments, can significantly impact patient care.
5. Longitudinal Studies and Prognostication: Expanding the focus to longitudinal studies that assess the evolution of prostate cancer over time can provide valuable insights into disease progression. Additionally, exploring deep learning applications for prognostication can aid in tailoring treatment strategies based on the predicted aggressiveness of the cancer.
6. Ethical and Regulatory Considerations: Addressing ethical considerations, patient privacy concerns, and ensuring compliance with regulatory standards are imperative. Future research should emphasize ethical AI practices and work towards establishing clear guidelines for the deployment of deep learning models in clinical settings.

By addressing the above challenges and expanding the scope of research, the field can contribute significantly to advancing personalized and precise prostate cancer care.

REFERENCES

[1] M. Nishio, H. Matsuo, Y. Kurata, O. Sugiyama, and K. Fujimoto, “Label Distribution Learning for Automatic Cancer Grading of Histopathological Images of Prostate Cancer,” Cancers, vol. 15, no. 5, pp. 1–12, 2023, doi: 10.3390/cancers15051535.

[2] A. Ramírez-Mena, E. Andrés-León, M. J. Alvarez-Cubero, A. Anguita-Ruiz, L. J. Martinez-Gonzalez, and J. Alcala-Fdez, “Explainable artificial intelligence to predict and identify prostate cancer tissue by gene expression,” Computer Methods and Programs in Biomedicine, vol. 240, 2023, doi: 10.1016/j.cmpb.2023.107719.

[3] A. Naeem, A. H. Khan, S. u din Ayubi, and H. Malik, “Predicting the Metastasis Ability of Prostate Cancer using Machine Learning Classifiers,” Journal of Computing & Biomedical Informatics, vol. 4, no. 02, 2023.

[4] L. J. Isaksson et al., “High-performance prediction models for prostate cancer radiomics,” Informatics in Medicine Unlocked, vol. 37, no. December 2022, p. 101161, 2023, doi: 10.1016/j.imu.2023.101161.

[5] A. Muazzam et al., “A Novel Blood Proteomic Signature for Prostate Cancer,” Cancers, vol. 15, no. 4, 2023, doi: 10.3390/cancers15041051.

[6] H. Kamecki et al., “Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients,” Cancers, vol. 15, no. 22, 2023, doi: 10.3390/cancers15225462.

[7] A. Singh, S. Randive, A. Breggia, B. Ahmad, R. Christman, and S. Amal, “Enhancing Prostate Cancer Diagnosis with a Novel Artificial Intelligence-Based Web Application: Synergizing Deep Learning Models, Multimodal Data, and Insights from Usability Study with Pathologists,” Cancers, vol. 15, no. 23, 2023, doi:

10.3390/cancers15235659.
[8] M. Oderda et al., “Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index,” Current Oncology, vol. 30, no. 5, pp. 4957–4965, 2023, doi: 10.3390/curroncol30050374.
[9] P. F. R. Wilson et al., “Self-Supervised Learning with Limited Labeled Data for Prostate Cancer Detection in High-Frequency Ultrasound,” IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 70, no. 9, pp. 1073–1083, 2023, doi: 10.1109/TUFFC.2023.3297840.
[10] R. Tibrewala et al., “FastMRI Prostate: A Publicly Available, Biparametric MRI Dataset to Advance Machine Learning for Prostate Cancer Imaging.,” ArXiv, 2023, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/37131871%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC10153282
[11] C. Dariane et al., “Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis,” World Journal of Urology, vol. 41, no. 3, pp. 641–651, 2023, doi: 10.1007/s00345-022-04087-z.
[12] B. M. R. International, “Retracted: Identification and Classification of Prostate Cancer Identification and Classification Based on Improved Convolution Neural Network,” BioMed research international, vol. 2023, p. 9804727, 2023, doi: 10.1155/2023/9804727.
[13] J. Chen et al., “A transfer learning nomogram for predicting prostate cancer and benign conditions on MRI,” BMC Medical Imaging, vol. 23, no. 1, pp. 1–12, 2023, doi: 10.1186/s12880-023-01163-7.
[14] M. S. Alzboon and M. S. Al-Batah, “Prostate Cancer Detection and Analysis using Advanced Machine Learning,” International Journal of Advanced Computer Science and Applications, vol. 14, no. 8, pp. 388–396, 2023, doi: 10.14569/IJACSA.2023.0140843.
[15] X. Huang, B. Pang, T. Zhang, G. Jia, Y. Wang, and Y. Li, “Improved Prostate Biparameter Magnetic Resonance Image Segmentation Based on Def-UNet,” IEEE Access, vol. 11, no. April, pp. 43089–43100, 2023, doi: 10.1109/ACCESS.2023.3268576.
[16] M. Varan, J. Azimjonov, and B. Macal, “Enhancing Prostate Cancer Classification by Leveraging Key Radiomics Features and Using the Fine-Tuned Linear SVM Algorithm,” IEEE Access, vol. 11, no. August, pp. 88025–88039, 2023, doi: 10.1109/ACCESS.2023.3306515.
[17] L. Zhao et al., “Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 3, pp. 727–741, 2023, doi: 10.1007/s00259-022-06036-9.
[18] T. N. Chu, E. Y. Wong, R. Ma, C. H. Yang, I. S. Dalieh, and A. J. Hung, “Exploring the Use of Artificial Intelligence in the Management of Prostate Cancer,” Current Urology Reports, vol. 24, no. 5, pp. 231–240, 2023, doi: 10.1007/s11934-023-01149-6.
[19] E. Checcucci et al., “Machine-Learning-Based Tool to Predict Target Prostate Biopsy Outcomes: An Internal Validation Study,” Journal of Clinical Medicine, vol. 12, no. 13, 2023, doi: 10.3390/jcm12134358.
[20] N. Rabilloud et al., “Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review,” Diagnostics, vol. 13, no. 16, 2023, doi: 10.3390/diagnostics13162676.
[21] S. K. Singh et al., “A novel deep learning-based technique for detecting prostate cancer in MRI images,” Multimedia Tools and Applications, no. 0123456789, 2023, doi: 10.1007/s11042-023-15793-0.
[22] Y. Bouslimi, T. Ben Aïcha Gader, and A. K. Echi, “Deep Learning-based Detection, Segmentation of Prostate Cancer from mp-MRI Images,” Electronic Letters on Computer Vision and Image Analysis, vol. 22, no. 1, pp. 52–76, 2023, doi: 10.5565/REV/ELCVIA.1620.
[23] P. E. Akhoondi and M. S. Baghshah, “Semantic Segmentation with Multiple Contradictory Annotations Using a Dynamic Score Function,” IEEE Access, vol. 11, no. June, pp. 64544–64558, 2023, doi: 10.1109/ACCESS.2023.3278275.
[24] L. Hu et al., “Automated deep-learning system in the assessment of MRI-visible prostate cancer: comparison of advanced zoomed diffusion-weighted imaging and conventional technique,” Cancer Imaging, vol. 23, no. 1, pp. 1–12, 2023, doi: 10.1186/s40644-023-00527-0.
[25] V. Panebianco and B. Turkbey, “Magnetic resonance imaging for prostate cancer recurrence: it’s time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score,” European Radiology, vol. 33, no. 2, pp. 748–751, 2023, doi: 10.1007/s00330-022-09095-6.
[26] J. M. Marrón-Esquivel, L. Duran-Lopez, A. Linares-Barranco, and J. P. Dominguez-Morales, “A comparative study of the inter-observer variability on Gleason grading against Deep Learning-based approaches for prostate cancer,” Computers in Biology and Medicine, vol. 159, no. February, 2023, doi: 10.1016/j.compbiomed.2023.106856.
[27] R. Seifert et al., “Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2),” European Urology, vol. 83, no. 5, pp. 405–412, 2023, doi: 10.1016/j.eururo.2023.02.002.
[28] N. Paesano, V. Catalá, L. Tcholakian, E. Trilla, and J. Morote, “A Systematic Review of the Current Status of

Magnetic Resonance–Ultrasound Images Fusion Software Platforms for Trans perineal Prostate Biopsies,” Cancers, vol. 15, no. 13, 2023, doi: 10.3390/cancers15133329.

[29] P. Gravestock, B. K. Somani, T. Tokas, and B. P. Rai, “A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide,” Journal of Clinical Medicine, vol. 12, no. 3, 2023, doi: 10.3390/jcm12031186.

[30] F. Abd Ali et al., “MRI-Guided Targeted and Systematic Prostate Biopsies as Prognostic Indicators for Prostate Cancer Treatment Decisions,” Cancers, vol. 15, no. 15, pp. 1–14, 2023, doi: 10.3390/cancers15153915.

[31] M. Boschheidgen et al., “MRI grading for the prediction of prostate cancer aggressiveness,” European Radiology, vol. 32, no. 4, pp. 2351–2359, 2022, doi: 10.1007/s00330-021-08332-8.

[32] J. Morote et al., “Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer,” Cancers, vol. 14, no. 7, pp. 1–9, 2022, doi: 10.3390/cancers14071828.

[33] S. Toledo-Cortés, D. H. Useche, H. Müller, and F. A. González, “Grading diabetic retinopathy and prostate cancer diagnostic images with deep quantum ordinal regression,” Computers in Biology and Medicine, vol. 145, no. 105472, 2022, doi: 10.1016/j.compbiomed.2022.105472.

[34] N. Singhal et al., “A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies,” Scientific Reports, vol. 12, no. 1, pp. 1–11, 2022, doi: 10.1038/s41598-022-07217-0.

[35] W. Li et al., “Diagnostic Performance of Extraprostatic Extension Grading System for Detection of Extraprostatic Extension in Prostate Cancer: A Diagnostic Systematic Review and Meta-Analysis,” Frontiers in Oncology, vol. 11, no. January, pp. 1–9, 2022, doi: 10.3389/fonc.2021.792120.

[36] W. Bulten et al., “Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge,” Nature Medicine, vol. 28, no. 1, pp. 154–163, 2022, doi: 10.1038/s41591-021-01620-2.

[37] G. Ramkumar et al., “Implementation of Machine Learning Mechanism for Recognizing Prostate Cancer through Photoacoustic Signal,” Contrast Media and Molecular Imaging, vol. 2022, 2022, doi: 10.1155/2022/6862083.

[38] R. Sammouda, A. Gumaei, and A. El-Zaart, “Intelligent Computer-Aided Prostate Cancer Diagnosis Systems: State-of-the-Art and Future Directions,” Mathematical Problems in Engineering, vol. 2021, 2021, doi: 10.1155/2021/9955174.

[39] L. Zhang et al., “Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature,” Contrast Media and Molecular Imaging, vol. 2021, 2021, doi: 10.1155/2021/7830909.

[40] A. H. M. Linkon, M. M. Labib, T. Hasan, M. Hossain, and M. E. Jannat, “Deep learning in prostate cancer diagnosis and Gleason grading in histopathology images: An extensive study,” Informatics in Medicine Unlocked, vol. 24, no. April, p. 100582, 2021, doi: 10.1016/j.imu.2021.100582.

[41] G. Ploussard et al., “Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction,” Journal of Clinical Medicine, vol. 9, no. 1, pp. 1–9, 2020, doi: 10.3390/jcm9010225.

[42] C. Siegel, “Re: A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI,” The Journal of urology, vol. 202, no. 3, pp. 440–441, 2019, doi: 10.1097/JU.0000000000000371.

[43] D. M. Berney et al., “Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome,” British Journal of Cancer, vol. 114, no. 10, pp. 1078–1083, 2016, doi: 10.1038/bjc.2016.86.

[44] J. I. Epstein, “A new contemporary prostate cancer grading system,” Annales de Pathologie, vol. 35, no. 6, pp. 474–476, 2015, doi: 10.1016/j.annpat.2015.09.002.

[45] V. Den Heuvel, “Pathologist-Level Grading of Prostate Biopsies with Artificial Intelligence,” Orca, pp. 1–2, 2014.

[46] A. C. Reese, J. E. Cowan, J. S. Brajtbord, C. R. Harris, P. R. Carroll, and M. R. Cooperberg, “The quantitative Gleason score improves prostate cancer risk assessment,” Cancer, vol. 118, no. 24, pp. 6046–6054, 2012, doi: 10.1002/cncr.27670.

[47] S. Verma et al., “Assessment of aggressiveness of prostate cancer: Correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy,” American Journal of Roentgenology, vol. 196, no. 2, pp. 374–381, 2011, doi: 10.2214/AJR.10.4441.

[48] N. Borley and M. R. Feneley, “Prostate cancer: Diagnosis and staging,” Asian Journal of Andrology, vol. 11, no. 1, pp. 74–80, 2009, doi: 10.1038/aja.2008.19.

[49] J. I. Epstein et al., “Pathological and molecular aspects of prostate cancer,” Lancet, vol. 361, pp. 955–64, 2003.

[50] Notestein, “A REPORT OF THE WORKSHOPS ON THE CURRENT STATUS OF THE HISTOLOGIC GRADING OF PROSTATE CANCER,” The Journal of biophysical and biochemical cytology, vol. 219, no. 3, pp. 214–219, 1973.